Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blinded, Parallel-Arm, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Study Followed by an Open-Label Arm to Evaluate Efgartigimod IV in Pediatric Participants From 12 Years to Less Than 18 Years of Age With Chronic ITP

NCT07194850 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT07194850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07194850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blinded, Parallel-Arm, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Study Followed by an Open-Label Arm to Evaluate Efgartigimod IV in Pediatric Participants From 12 Years to Less Than 18 Years of Age With Chronic ITP
Lead sponsor
argenx
Phase
Phase 2/3
Overall status
Recruiting
Start date
October 20, 2025
Completion date
October 31, 2030
Enrollment
24 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic thrombocytopenic purpura, idiopathic thrombocytopenic purpura (itp), immune thrombocytopenia (itp), immune thrombocytopenic purpura, immune thrombocytopenic purpura ( itp ), itp, itp - immune thrombocytopenia